RxDoctor Payments Data

Mary O'Meara, MD

Family Medicine · Vero Beach, FLNPI 1356761258

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 39 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$301
  • Dexcom, Inc.$233
  • Mayne Pharma Commercial LLC$123
  • Lupin Inc.$115
  • GSK$77
  • Novo Nordisk$70
  • plus $263 from 11 others

What the payments were for

  • Food & beverage$1,16198%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,253
Medicare patients
12
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$29,366
JardianceEmpagliflozin21$24,783
JanuviaSitagliptin Phosphate15$13,687
OzempicSemaglutide15$12,838
XareltoRivaroxaban13$10,579
Levothyroxine Sodium232$2,449
SynthroidLevothyroxine Sodium22$2,255
Rosuvastatin Calcium119$2,046
Atorvastatin Calcium216$1,879
Omeprazole80$1,328
Amlodipine Besylate149$1,014
Bupropion XlBupropion Hcl22$877
Lisinopril129$866
Losartan Potassium94$846
Metoprolol Succinate60$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$29,36621 claims
Boehringer IngelheimJardiance$26$24,78321 claims
MerckJanuvia$16$13,68715 claims
Novo NordiskOzempic$70$12,83815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →